Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Myeloproliferative Neoplasms: Myelofibrosis
Join Katalin Kelemen, MD, PhD and Ruben A. Mesa, MD from Mayo Clinic Cancer Center as they present their expertise on a range of cases pertaining to myeloproliferative neoplasms, with a specific focus on myelofibrosis.
Myelofibrosis (MF) is one of the BCR-ABL1-negative myeloproliferative neoplasms (MPN). This group also includes polycythemia vera (PV) and essential thrombocythemia (ET). MPNs are associated with a risk of transformation to acute myeloid leukemia, and the incidence is more frequent in patients with MF. The selection of treatment is based on the risk score and the presence of symptoms.
The goal of therapy in patients with MF is to reduce symptom burden and minimize the risk of leukemic transformation. Identification of mutations implicated in pathogenesis of MF has led to the development of novel therapeutic approaches that have resulted in significant improvements in disease-related symptoms. Nevertheless, management of MF continues to present challenges for hematologists/oncologists. Appropriate assessments of symptom burden and risk stratification are essential to develop an effective symptom-directed approach based on the patient’s clinical needs. After initiation of treatment, regular monitoring of symptoms is essential and a change in symptom status should prompt evaluation of treatment efficacy so that alternate options can be considered. Clinicians need to remain knowledgeable about emerging therapeutic strategies and the need for regular monitoring of symptoms.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Assess the clinical evidence supporting the use of JAK2 inhibitors and other novel therapies in the management of myelofibrosis.
- Develop an individualized treatment plan for primary myelofibrosis incorporating the currently approved JAK2 inhibitor based on the risk stratification and symptom assessment.
- Regularly monitor symptoms and evaluate treatment efficacy after initial treatment.
Katalin Kelemen, MD, PhD
Mayo Clinic Cancer Center
Ruben A. Mesa, MD
Mayo Clinic Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below has no relevant financial relationships to disclose:
Katalin Kelemen, MD, PhD
The faculty listed below have disclosed the following relevant financial relationships:
Ruben A. Mesa, MD
ARIAD Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Celgene Corporation: Grant/Research Support
CTI BioPharma Corp.: Grant/Research Support
Galena Biopharma, Inc.: Consulting Fees, Honoraria
Gilead Sciences, Inc.: Grant/Research Support
Incyte Corporation: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria
Promedior, Inc.: Grant/Research Support
The activity planning staff listed below has no relevant financial relationships to disclose:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Mary Anne Bergman; Hema Sundar, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00023956; Approval #: 160004415
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-107-L01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation